253 related articles for article (PubMed ID: 2547935)
41. Effect of chronic administration of U-50,488H, a kappa-opioid receptor agonist, on central dopamine D2 receptors of the rat.
Veeranna ; Reddy PL; Bhargava HN
Eur J Pharmacol; 1993 Apr; 235(1):23-30. PubMed ID: 8390939
[TBL] [Abstract][Full Text] [Related]
42. Pharmacodynamic and pharmacokinetic actions of ketocyclazocine enantiomers in the dog: absence of sigma- or phencyclidine-like activity.
Vaupel DB; Cone EJ
J Pharmacol Exp Ther; 1991 Jan; 256(1):211-21. PubMed ID: 1846414
[TBL] [Abstract][Full Text] [Related]
43. Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50,488H, a kappa-opioid receptor agonist, in the mouse.
Bhargava HN; Thorat SN
Brain Res; 1994 Jun; 649(1-2):111-6. PubMed ID: 7953621
[TBL] [Abstract][Full Text] [Related]
44. Antitussive effects of two specific kappa-opioid agonists, U-50,488H and U-62,066E, in rats.
Kamei J; Tanihara H; Kasuya Y
Eur J Pharmacol; 1990 Oct; 187(2):281-6. PubMed ID: 2272363
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
Pugsley MK; Penz WP; Walker MJ; Wong TM
Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
[TBL] [Abstract][Full Text] [Related]
46. Down-regulation of central receptors for thyrotropin-releasing hormone in kappa opiate agonist-induced abstinence in the rat.
Bhargava HN; Gulati A; Rahmani NH
Neuropharmacology; 1992 Feb; 31(2):137-41. PubMed ID: 1313157
[TBL] [Abstract][Full Text] [Related]
47. Abstinence from U-50,488H, a kappa-opiate receptor agonist, decreases the binding of [3H]DPAT to 5-HT1A receptors in the hypothalamus of the rat.
Reddy VP; Bhargava HN
Neuropharmacology; 1992 Dec; 31(12):1243-9. PubMed ID: 1470300
[TBL] [Abstract][Full Text] [Related]
48. Biochemical and behavioral studies on the interaction between mu- and kappa-opiate agonists in mice.
Thorat SN; Veeranna ; Reddy PL; Bhargava HN
Brain Res; 1993 Jul; 615(2):191-8. PubMed ID: 8395957
[TBL] [Abstract][Full Text] [Related]
49. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
Ukai M; Kameyama T
Brain Res; 1985 Jul; 337(2):352-6. PubMed ID: 2992682
[TBL] [Abstract][Full Text] [Related]
50. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
Suzuki T; Izumimoto N; Takezawa Y; Fujimura M; Togashi Y; Nagase H; Tanaka T; Endoh T
Brain Res; 2004 Jan; 995(2):167-75. PubMed ID: 14672806
[TBL] [Abstract][Full Text] [Related]
51. Contrasting influences of 5-hydroxytryptamine receptors in nitrous oxide antinociception in mice.
Mueller JL; Quock RM
Pharmacol Biochem Behav; 1992 Feb; 41(2):429-32. PubMed ID: 1533464
[TBL] [Abstract][Full Text] [Related]
52. Non-competitive antagonism of N-methyl-D-aspartate receptor inhibits tolerance to the analgesic action of U-50,488H, a kappa-opiate receptor agonist in the rat.
Bhargava HN
Gen Pharmacol; 1995 Sep; 26(5):1055-60. PubMed ID: 7557250
[TBL] [Abstract][Full Text] [Related]
53. Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, O-Desmethyltramadol, via activation of descending serotonergic pathways.
Yanarates O; Dogrul A; Yildirim V; Sahin A; Sizlan A; Seyrek M; Akgül O; Kozak O; Kurt E; Aypar U
Anesthesiology; 2010 Mar; 112(3):696-710. PubMed ID: 20179508
[TBL] [Abstract][Full Text] [Related]
54. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
55. Dynorphin prolongs the action potential duration of mouse sensory ganglion neurons by decreasing a K+ conductance whereas the specific kappa opioid, U-50,488H does so by increasing a Ca2+ conductance.
Shen KF; Crain SM
Prog Clin Biol Res; 1990; 328():343-6. PubMed ID: 1968268
[No Abstract] [Full Text] [Related]
56. Differential effects of LY235959, a competitive antagonist of the NMDA receptor on kappa-opioid receptor agonist induced responses in mice and rats.
Bhargava HN; Thorat SN
Brain Res; 1997 Feb; 747(2):246-51. PubMed ID: 9045999
[TBL] [Abstract][Full Text] [Related]
57. Modulation of kappa-opioid receptor mediated tolerance in the guinea-pig ileum by chronic co-administration of dihydropyridines.
Garaulet JV; Laorden ML; Milanés MV
Naunyn Schmiedebergs Arch Pharmacol; 1996 Jun; 354(1):72-9. PubMed ID: 8832591
[TBL] [Abstract][Full Text] [Related]
58. Effect of repeated administration of U-50,488H on the binding of 3H-SCH 23390 and 3H-spiperone to rat brain and spinal cord dopamine receptors.
Bhargava HN; Ramarao P; Gulati A
Prog Clin Biol Res; 1990; 328():153-6. PubMed ID: 2406759
[No Abstract] [Full Text] [Related]
59. The effect of U-50,488H, a kappa-opiate receptor agonist on tolerance to the analgesic and hyperthermic effects of morphine in the rat.
Bhargava HN; Matwyshyn G; Ramarao P
Gen Pharmacol; 1991; 22(3):429-34. PubMed ID: 1651266
[TBL] [Abstract][Full Text] [Related]
60. Chronic kappa opioid receptor antagonism produces supersensitivity to U-50,488H at the hypothalamo-pituitary-adrenocortical (HPA) axis level.
Alcaraz C; Milanés MV; Vargas ML
J Pharmacol Exp Ther; 1993 Sep; 266(3):1385-9. PubMed ID: 8396634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
